The immunomodulatory effects of barettin and involvement of the kinases CAMK1α and RIPK2

References

• Lind KF, Hansen E, Osterud B, et al. Antioxidant and anti-inflammatory activities of barettin. Mar Drugs 2013;11:2655–2666
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723–737
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456s–460s
   PubMed Web of Science ®Google Scholar
• Itabe H, Obama T, Kato R. The dynamics of oxidized LDL during atherogenesis. J Lipids 2011;2011:9
   Google Scholar
• Claise C, Edeas M, Chaouchi N, et al. Oxidized-LDL induce apoptosis in HUVEC but not in the endothelial cell line EA.hy 926. Atherosclerosis 1999;147:95–104
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the ‘response to injury’ hypothesis. Circulation 1997;95:1760–1763
   PubMed Web of Science ®Google Scholar
• Valente AJ, Irimpen AM, Siebenlist U, Chandrasekar B. OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators. Free Radic Biol Med 2014;70:117–128
   PubMed Web of Science ®Google Scholar
• Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal 2009;5:107–115
   PubMed Web of Science ®Google Scholar
• Muller S, Knapp S. Targeting kinases for the treatment of inflammatory diseases. Expert Opin Drug Discov 2010;5:867–881
   PubMed Web of Science ®Google Scholar
• Cohen P, Alessi DR. Kinase drug discovery – what’s next in the field? ACS Chem Biol 2012;8:96–104
   PubMed Web of Science ®Google Scholar
• Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007;57:1046–1050
   PubMed Web of Science ®Google Scholar
• Ballou L, Lin R. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008;1:27–36
   PubMedGoogle Scholar
• Lee YW, Lee WH, Kim PH. Oxidative mechanisms of IL-4-induced IL-6 expression in vascular endothelium. Cytokine 2010;49:73–79
   PubMed Web of Science ®Google Scholar
• Hunt AE, Williams LM, Lali FV, Foxwell BMJ. IL-4 regulation of p38 MAPK signalling is dependent on cell type. Cytokine 2002;18:295–303
   PubMed Web of Science ®Google Scholar
• Hart PH, Vitti GF, Burgess DR, et al. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989;86:3803–3807
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209–1220
   PubMed Web of Science ®Google Scholar
• Woodward EA, Kolesnik TB, Nicholson SE, et al. The anti-inflammatory actions of IL-4 in human monocytes are not mediated by IL-10, RP105 or the kinase activity of RIPK2. Cytokine 2012;58:415–423
   PubMed Web of Science ®Google Scholar
• Hazen SL. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J Biol Chem 2008;283:15527–15531
   PubMed Web of Science ®Google Scholar
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204–212
   PubMed Web of Science ®Google Scholar
• Park HJ, Zhang Y, Georgescu SP, et al. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev 2006;2:93–102
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–874
   PubMed Web of Science ®Google Scholar
• Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410–1422
   PubMed Web of Science ®Google Scholar
• Lee YW, Hennig B, Toborek M. Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. Am J Physiol Heart C 2003;284:H185–H192
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo L, Collage RD, et al. Calcium/calmodulin-dependent protein kinase (CaMK) Ialpha mediates the macrophage inflammatory response to sepsis. J Leukoc Biol 2011;90:249–261
   PubMed Web of Science ®Google Scholar
• Wong-Ekkabut J, Xu Z, Triampo W, et al. Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. Biophys J 2007;93:4225–4236
   PubMed Web of Science ®Google Scholar
• Halliwell B. Free radicals in biology and medicine. 4th ed. Oxford, UK: Oxford University Press; 2007
   Google Scholar
• Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275–281
   PubMed Web of Science ®Google Scholar
• Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121–1127
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313–326
   PubMed Web of Science ®Google Scholar
• Yin X, Krikorian P, Logan T, Csizmadia V. Induction of RIP-2 kinase by proinflammatory cytokines is mediated via NF-kappaB signaling pathways and involves a novel feed-forward regulatory mechanism. Mol Cell Biochem 2010;333:251–259
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 2005;30:151–159
   PubMed Web of Science ®Google Scholar
• McCarthy JV, Ni J, Dixit VM. RIP2 is a novel NF-κB-activating and cell death-inducing kinase. J Biol Chem 1998;273:16968–16975
   PubMed Web of Science ®Google Scholar
• Chin AI, Dempsey PW, Bruhn K, et al. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 2002;416:190–194
   PubMed Web of Science ®Google Scholar
• Rickard DJ, Sehon CA, Kasparcova V, et al. Identification of selective small molecule inhibitors of the nucleotide-binding oligomerization domain 1 (NOD1) signaling pathway. PLoS One 2014;9:e96737
   PubMedGoogle Scholar
• Thome M, Hofmann K, Burns K, et al. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol 1998;8:885–888
   PubMed Web of Science ®Google Scholar
• Humke EW, Shriver SK, Starovasnik MA, et al. ICEBERG: a novel inhibitor of interleukin-1beta generation. Cell 2000;103:99–111
   PubMed Web of Science ®Google Scholar
• Druilhe A, Srinivasula SM, Razmara M, et al. Regulation of IL-1beta generation by Pseudo-ICE and ICEBERG, two dominant negative caspase recruitment domain proteins. Cell Death Differ 2001;8:649–657
   PubMed Web of Science ®Google Scholar
• Lu C, Wang A, Dorsch M, et al. Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity. J Biol Chem 2005;280:16278–16283
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002;416:194–199
   PubMed Web of Science ®Google Scholar
• Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847–2853
   PubMed Web of Science ®Google Scholar
• Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000;181:176–180
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Solak Y, Saglam M, et al. The relationship between IL-10 levels and cardiovascular events in patients with CKD. Clin J Am Soc Nephrol 2014;9:1207–1216
   PubMed Web of Science ®Google Scholar
• Liu J, Hu Y, Waller DL, et al. Natural products as kinase inhibitors. Nat Prod Rep 2012;29:392–403
   PubMed Web of Science ®Google Scholar
• Levin MC, Jirholt P, Wramstedt A, et al. Rip2 deficiency leads to increased atherosclerosis despite decreased inflammation. Circ Res 2011;109:1210–1218
   PubMed Web of Science ®Google Scholar
• Gaestel M, Mengel A, Bothe U, Asadullah K. Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem 2007;14:2214–2234
   PubMed Web of Science ®Google Scholar
• Joshi S, Platanias LC. Mnk kinase pathway: cellular functions and biological outcomes. World J Biol Chem 2014;5:321–333
   PubMedGoogle Scholar